Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in refractory or relapsed multiple myeloma
DRKS00003074Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in multiple myeloma (MM), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Safety and tolerability of vorinostat in combination with bortezomib, doxorubicin, and dexamethasone. Started Jul 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on DRKS00003074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003074.